GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shuttle Pharmaceuticals Holdings Inc (NAS:SHPH) » Definitions » EV-to-EBIT

Shuttle Pharmaceuticals Holdings (Shuttle Pharmaceuticals Holdings) EV-to-EBIT : -0.64 (As of May. 15, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Shuttle Pharmaceuticals Holdings EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Shuttle Pharmaceuticals Holdings's Enterprise Value is $2.62 Mil. Shuttle Pharmaceuticals Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.10 Mil. Therefore, Shuttle Pharmaceuticals Holdings's EV-to-EBIT for today is -0.64.

The historical rank and industry rank for Shuttle Pharmaceuticals Holdings's EV-to-EBIT or its related term are showing as below:

SHPH' s EV-to-EBIT Range Over the Past 10 Years
Min: -273.26   Med: 0   Max: 0.25
Current: -0.64

During the past 4 years, the highest EV-to-EBIT of Shuttle Pharmaceuticals Holdings was 0.25. The lowest was -273.26. And the median was 0.00.

SHPH's EV-to-EBIT is ranked worse than
100% of 667 companies
in the Drug Manufacturers industry
Industry Median: 17.74 vs SHPH: -0.64

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Shuttle Pharmaceuticals Holdings's Enterprise Value for the quarter that ended in Dec. 2023 was $2.93 Mil. Shuttle Pharmaceuticals Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.10 Mil. Shuttle Pharmaceuticals Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -139.75%.


Shuttle Pharmaceuticals Holdings EV-to-EBIT Historical Data

The historical data trend for Shuttle Pharmaceuticals Holdings's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shuttle Pharmaceuticals Holdings EV-to-EBIT Chart

Shuttle Pharmaceuticals Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - -9.22 -0.72

Shuttle Pharmaceuticals Holdings Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.22 -5.01 -3.48 -1.05 -0.72

Competitive Comparison of Shuttle Pharmaceuticals Holdings's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Shuttle Pharmaceuticals Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shuttle Pharmaceuticals Holdings's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shuttle Pharmaceuticals Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shuttle Pharmaceuticals Holdings's EV-to-EBIT falls into.



Shuttle Pharmaceuticals Holdings EV-to-EBIT Calculation

Shuttle Pharmaceuticals Holdings's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=2.619/-4.101
=-0.64

Shuttle Pharmaceuticals Holdings's current Enterprise Value is $2.62 Mil.
Shuttle Pharmaceuticals Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shuttle Pharmaceuticals Holdings  (NAS:SHPH) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Shuttle Pharmaceuticals Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-4.101/2.9345315
=-139.75 %

Shuttle Pharmaceuticals Holdings's Enterprise Value for the quarter that ended in Dec. 2023 was $2.93 Mil.
Shuttle Pharmaceuticals Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shuttle Pharmaceuticals Holdings EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Shuttle Pharmaceuticals Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Shuttle Pharmaceuticals Holdings (Shuttle Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
N/A
Address
One Research Court, Suite 450, Rockville, MD, USA, 20850
Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy.
Executives
Milton Brown director SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Bette Jacobs director SHUTTLE PHARMACEUTICALS HOLDINGS, INC., 1 RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Peter Dritschilo officer: President and COO SHUTTLE PHARMACEUTICALS HOLDINGS, INC., SUITE 450, ROCKVILLE MD 20850
Anatoly Dritschilo director, 10 percent owner, officer: CEO and Chairman SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Tyvin Rich officer: Chief Medical Officer SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Mira Jung officer: Chief Scientific Officer SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Hoek Michael Vander officer: Chief Financial Officer SHUTTLE PHARMACEUTICALS HOLDINGS, INC., SUITE 450, ROCKVILLE MD 20850
Steven M Richards director SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
William Adkins director SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Joshua Schafer director SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Chris Senanayake director SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850